Prognostic Determinants in Prostate Cancer

AbstractClinical outcomes in prostate cancer are heterogeneous, and given the high prevalence of the disease, there is a pressing need to identify clinically useful markers of prognosis. Many clinical, pathological, molecular, and genetic factors have been investigated in this capacity, although relatively few are routinely used. With a growing understanding of the molecular pathogenesis of prostate cancer, there is the potential that the next generation of makers will prove sufficiently robust to guide the optimal management of men with prostate cancer. Here, we review the various clinical and molecular prognostic determinants in prostate cancer.

[1]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[2]  M. Desai,et al.  Accuracy of the Kattan nomogram across prostate cancer risk‐groups , 2011, BJU international.

[3]  T. Golub,et al.  mRNA expression signature of Gleason grade predicts lethal prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[5]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[6]  Misop Han,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[7]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[8]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[9]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[10]  M. Loda,et al.  Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[12]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[13]  Shuming Nie,et al.  Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. , 2010, ACS nano.

[14]  Mehmet Toner,et al.  Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer , 2010, Science Translational Medicine.

[15]  A. Ruffion,et al.  Urinary prostate cancer 3 test: toward the age of reason? , 2010, Urology.

[16]  C. Lawton,et al.  Screening and Prostate-Cancer Mortality in a Randomized European Study , 2010 .

[17]  R. DePinho,et al.  Telomeres and telomerase in cancer. , 2010, Carcinogenesis.

[18]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[19]  Stacey A. Kenfield,et al.  Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. DiPaola,et al.  Contemporary risk profile of prostate cancer in the United States. , 2009, Journal of the National Cancer Institute.

[21]  Andrew J Vickers,et al.  Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Haese*,et al.  TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[23]  Jing Ma,et al.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Kantoff,et al.  Evaluation of the 8q24 prostate cancer risk locus and MYC expression. , 2009, Cancer research.

[25]  H. Hricak,et al.  Imaging , Diagnosis , Prognosis Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles , 2009 .

[26]  L. Fink,et al.  Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors , 2009, Cancer Epidemiology Biomarkers & Prevention.

[27]  Hong Dai,et al.  Imaging , Diagnosis , Prognosis Prognostic Value of Akt1 in Human Prostate Cancer : A Computerized Quantitative Assessment with Quantum Dot Technology , 2009 .

[28]  J. Concato,et al.  Molecular Markers and Death From Prostate Cancer , 2009, Annals of Internal Medicine.

[29]  W. Hahn,et al.  Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. , 2009, Journal of the National Cancer Institute.

[30]  D. Dearnaley,et al.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.

[31]  Angela Mariotto,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[32]  Oscar Lin,et al.  Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[33]  W. Gerald,et al.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.

[34]  Pierre I Karakiewicz,et al.  Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. , 2009, The Journal of urology.

[35]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[36]  D. Dearnaley,et al.  Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  S. Srivastava,et al.  PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. , 2008, The Journal of urology.

[38]  J. Köllermann,et al.  Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[40]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[41]  B. Trask,et al.  Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. , 2008, Cancer research.

[42]  R. Babaian,et al.  Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. , 2008, The Journal of urology.

[43]  Ruud H. Brakenhoff,et al.  Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.

[44]  J. Mosley,et al.  Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists , 2008, BMC Medical Genomics.

[45]  Matthew Sydes,et al.  Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. , 2008, The Lancet. Oncology.

[46]  S. Boorjian,et al.  Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. , 2008, The Journal of urology.

[47]  Jianjun Yu,et al.  A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. , 2008, Cancer research.

[48]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[49]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[50]  Glenn Heller,et al.  Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[51]  A. Haese*,et al.  Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer , 2007, Clinical Cancer Research.

[52]  J. Witjes,et al.  Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer , 2007, Clinical Cancer Research.

[53]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[54]  S. Fosså,et al.  Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy , 2007, International Journal of Cancer.

[55]  P. Lichter,et al.  Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays , 2006, British Journal of Cancer.

[56]  M. Mason,et al.  The prognostic significance of perineural invasion in prostatic cancer biopsies , 2007, Cancer.

[57]  Lei Wang,et al.  Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. , 2006, Neoplasia.

[58]  Lennart Franzén,et al.  How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. , 2006, The Journal of urology.

[59]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[60]  P. Scardino,et al.  Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). , 2005, Urology.

[61]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[62]  James A Hanley,et al.  Prostate cancer and the Will Rogers phenomenon. , 2005, Journal of the National Cancer Institute.

[63]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[64]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[65]  T. Thompson,et al.  Erratum: High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence (Clinical Cancer Research (Octobet 1, 2004) 10 (6572-6578)) , 2005 .

[66]  J. Manola,et al.  Prognostic Significance of Baseline Reverse Transcriptase-PCR for Prostate-Specific Antigen in Men with Hormone-Refractory Prostate Cancer Treated with Chemotherapy , 2005, Clinical Cancer Research.

[67]  Robert A Gardiner,et al.  Use of multiple biomarkers for a molecular diagnosis of prostate cancer , 2005, International journal of cancer.

[68]  P. Walsh,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.

[69]  N. Joste,et al.  Association between cancer-free survival and telomere DNA content in prostate tumors. , 2005, The Journal of urology.

[70]  Liang Cheng,et al.  Perineural invasion in radical prostatectomy specimens: lack of prognostic significance. , 2004, The Journal of urology.

[71]  Jaime Pujadas Oláno,et al.  Natural history of early localized prostate cancer. , 2004, JAMA.

[72]  P. Scardino,et al.  High Levels of Phosphorylated Form of Akt-1 in Prostate Cancer and Non-Neoplastic Prostate Tissues Are Strong Predictors of Biochemical Recurrence , 2004, Clinical Cancer Research.

[73]  M. Hammond,et al.  Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Alexandra L Hanlon,et al.  Prostate cancer radiotherapy dose response: an update of the fox chase experience. , 2004, The Journal of urology.

[75]  P. Scardino,et al.  Expression of vascular endothelial growth factor receptor‐3 (VEGFR‐3) in human prostate , 2004, The Prostate.

[76]  Gurkamal Chatta,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy , 2003 .

[77]  Michael W Kattan,et al.  The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Ming-Hui Chen,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.

[79]  John T. Wei,et al.  Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. , 2003, Urologic oncology.

[80]  P. Walsh A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2003, The Journal of urology.

[81]  O. Halvorsen,et al.  Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  M. Kattan,et al.  The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer , 2003, The Prostate.

[83]  P. Abrahamsson,et al.  Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. , 2003, The Journal of urology.

[84]  J Wade Harper,et al.  Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[86]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.

[87]  H. Frierson,et al.  Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years , 2002, Cancer.

[88]  P. Kantoff,et al.  Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  M. Kattan,et al.  Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  E. Bergstralh,et al.  Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. , 2001, The Journal of urology.

[91]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[92]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[93]  J. Serth,et al.  Article no. bjoc.1999.0806 , 2022 .

[94]  D. Bostwick,et al.  Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.

[95]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[96]  John T. Wei,et al.  BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. , 1999, The Journal of urology.

[97]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[98]  M. Kattan,et al.  Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  C. Cordon-Cardo,et al.  Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[100]  V. Kosma,et al.  Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer , 1999, The Prostate.

[101]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[102]  A. Borkowski,et al.  bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. , 1998, Urology.

[103]  Pär Stattin,et al.  Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer , 1998, The Prostate.

[104]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[105]  M. Banerjee,et al.  Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  A. Nagafuchi,et al.  Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. , 1997, Cancer research.

[107]  F. Mostofi,et al.  Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. , 1996, The Journal of urology.

[108]  J W Moul,et al.  Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. , 1996, The Journal of urology.

[109]  J. Moul,et al.  p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[110]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[111]  F. Marshall,et al.  Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. , 1995, Urology.

[112]  J W Moul,et al.  Infrequent RAS oncogene mutations in human prostate cancer , 1992, The Prostate.

[113]  T. Stamey,et al.  The role of perineural space invasion in the local spread of prostatic adenocarcinoma. , 1989, The Journal of urology.

[114]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.